|
|
|
|
|
Metoclopramide
drug data and news
Metoclopramide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Metoclopramide | ||
| Brand Names/Synonyms | Apo-Metoclop; CHEMBANK734; Cerucal; Clopra; Clopra-Yellow; Clopromate; DEL; DEL 1267; DEL-1267; Duraclamid; Elieten; Emetid; Emperal; Eucil; Gastrese; Gastro-Timelets; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; M0763; M117; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida [Inn-Spanish]; Metoclopramide; Metoclopramide Hcl; Metoclopramide Hydrochloride; Metoclopramide Intensol; Metoclopramide Omega; Metoclopramidum [Inn-Latin]; Metocobil; Metramid; Moriperan; Mygdalon; Neu-Sensamide; Nu-Metoclopramide; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pms-Metoclopramide; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan | ||
| Indication | For the treatment of gastroesophageal reflux disease (GERD) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Metoclopramide, although chemically related to procainamide, does not possess local anesthetic or antiarrhythmic properties. Metoclopramide is used to enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation of the small bowel during radiologic examination. Metoclopramide may be used to treat chemotherapy-induced emesis and as a radiosensitizing agents in the treatment of non-small cell lung carcinoma and glioblastomas in the future. | ||
| Mechanism Of Action | Metoclopramide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in an improved coordination between the body and antrum of the stomach and the upper small intestine. Metoclopramide also decreases reflux into the esophagus by increasing the resting pressure of the lower esophageal sphincter and improves acid clearance from the esophagus by increasing amplitude of esophageal peristaltic contractions. Metoclopramide's dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves. Studies have also shown that high doses of metoclopramide can antagonize 5-hydroxytryptamine (5-HT) receptors in the peripheral nervous system in animals. | ||
| Metoclopramide News (When available) |
Stratified Care = Better Outcome Feb 28, 2006 Misdosing of Medications Prompts Most Poison Calls About Young ... Mar 1, 2006 FDA Joins Investigation of Infants’ Deaths Believed to Have Been ... Feb 26, 2006 Health Tip: Drugs to Avoid While Breast-Feeding Feb 16, 2006 Akathisia as a risk factor for suicide Feb 9, 2006 A Horrific Case of Hiccups, a Novel Treatment Jan 9, 2006 Children Remain Highly Vulnerable to Potentially Deadly Medication ... Jan 13, 2006 Nutritional Care in the ICU Jan 17, 2006 International Approvals: Zydena, MT-100, 3 Botanical Products Dec 5, 2005 Pozen gets British MT 100 approval Nov 28, 2005 Dissolvable Aspirin Effective for Migraine Nov 23, 2005 POZEN Receives Approval for MT 100 in the United Kingdom Nov 28, 2005 Infants Dying as a Result of Overdosing with Over-the-Counter Cold ... Nov 17, 2005 Cheap branded drugs soon available in Botika ng Bayan Sep 9, 2005 Iron deficiency can cause restless leg syndrome Aug 30, 2005 Pralidoxime Rescues Both Muscarinic and Nicotinic Systems Aug 22, 2005 Capsule endoscopy Aug 9, 2005 Pozen drops one migraine drug, to pursue another Aug 5, 2005 Pozen to argue for safety of migraine drug Aug 3, 2005 Erythromycin Antagonizes the Deceleration of Gastric Emptying By ... Jul 10, 2005 Peripheral and Central Nervous System Drugs Advisory Committee Aug 1, 2005 POZEN Reports Second Quarter 2005 Results; Trexima(TM) NDA on ... Jul 28, 2005 Acute Akathisia Associated With Quetiapine Use Jul 6, 2005 When home remedies for hiccups fail, medicines can usually end ... Jul 20, 2005 Erythromycin Antagonizes the Deceleration of Gastric Emptying By ... Jul 10, 2005 Acute Akathisia Associated With Quetiapine Use Jul 6, 2005 FDA sets date for crucial meeting on Pozen drug Jun 29, 2005 Ondansetron Oral Disintegrating Tablets: Acceptability and ... Jun 23, 2005 | ||
| Dosage Forms | LIQUID; SYRUP; TABLET | ||
| Drug_Category | Antiemetics; Prokinetic Agents; Dopamine Antagonists; ATC:A03FA01 | ||
| Absorption | Rapidly and well absorbed (oral bioavailability 80±15.5%). | ||
| Interactions | DRUG INTERACTIONS The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients. Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia. Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment. | ||
| Toxicity | Oral, mouse LD50: 280 mg/kg. Signs of overdose include drowsiness, disorientation, and extrapyramidal reactions. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxy-benzamide | ||
| Chemical Formula | C14H22ClN3O2 | ||
| Molecular Weight | 299.796 g/mol | ||
| Smiles String | CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl | ||
| Melting Point | 147.25 °C | ||
| Water Solubility | 200 mg/L | ||
| State | Solid (white crystalline, odorless substance) | ||
| LogP/Hphobicity | 2.464 | ||
| Isoelectric Point | 9.27 | ||
| Biotransformation | Hepatic | ||
| Half Life | 5-6 hr | ||
| Protein Binding [%] | 30% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Metoclopramide.html http://www.rxlist.com/cgi/generic2/metoclo.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/reg1369.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00665 | ||
| CAS Registry Number | 364-62-5 | ||
| KEGG Compound ID | C07868 | ||
| PubChem ID | SID:152911 | ||
| PharmGKB ID | PA450475 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2243563 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |